Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
- PMID: 32283230
- PMCID: PMC7151529
- DOI: 10.1016/j.jaad.2020.04.030
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
References
-
- United States Food and Drug Administration . 2015. Adalimumab [package insert] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125057s394lbl.pdf. Accessed April 27, 2020.
-
- Kimball A.B., Okun M.M., Williams D.A., et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
